CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
1.090
-0.010 (-0.91%)
At close: Dec 20, 2024, 4:00 PM
1.067
-0.023 (-2.11%)
After-hours: Dec 20, 2024, 6:50 PM EST
CytomX Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for CytomX Therapeutics stock have an average target of 5.77, with a low estimate of 3.50 and a high estimate of 8.00. The average target predicts an increase of 429.36% from the current stock price of 1.09.
Analyst Consensus: Buy
* Price targets were last updated on May 28, 2024.
Analyst Ratings
The average analyst rating for CTMX stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Sep 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jun 27, 2024 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $2.25 → $3.5 | Hold → Buy | Upgrades | $2.25 → $3.5 | +221.10% | May 28, 2024 |
Financial Forecast
Revenue This Year
124.04M
from 101.21M
Increased by 22.55%
Revenue Next Year
82.17M
from 124.04M
Decreased by -33.76%
EPS This Year
-0.04
from -0.01
EPS Next Year
-0.44
from -0.04
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 139.7M | 138.6M | 88.9M | |||
| Avg | 124.0M | 82.2M | 34.3M | |||
| Low | 110.3M | 30.4M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 38.0% | 11.7% | 8.2% | |||
| Avg | 22.6% | -33.8% | -58.2% | |||
| Low | 8.9% | -75.5% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 0.15 | -0.13 | -0.46 | |||
| Avg | -0.04 | -0.44 | -0.78 | |||
| Low | -0.37 | -0.93 | -1.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.